Assessment of BCR-ABL1 Fusion Transcripts and Their Association with Response to Imatinib Treatment in Chronic Myeloid Leukemia Patients

Abstract

Objectives: BCR-ABL1 fusion transcripts with contrasting data on response to imatinib therapy have been reported from different parts of the world. Hence, the present study aimed to determine the frequencies of transcripts and their association with response to imatinib therapy in chronic myeloid leukemia (CML) patients. Methods: A total of 170 (76 follow-up and 94 imatinib-resistant) CML samples were included in the study. BCR-ABL1 fusion transcripts and expression status were analyzed in all cases using multiplex reverse transcriptase PCyR and real-time PCyR. Sanger sequencing was used for tyrosine kinase domain (TKD) mutation screening in imatinib mesylate-resistant patients. Results: Of 170 CML patients, 36.36% showed b2a2, 63.53% had b3a2, and 2.94% had b2a2 + b3a2 isoforms. Mean platelet counts and blasts were significantly lower in b2a2 carriers (P = 0.0092; P ≤ 0.0001). Patients with b2a2 transcript were found to be more in responders group (both hematological and cytogenetic), whereas b3a2 patients were more in partial responders group and death (P = 0.763; P = 0.309). In follow-up patients, mean baseline BCR-ABL1 expression levels are significantly higher in b2a2 versus b3a2 carriers (P = 0.0351). Of 94 imatinib-resistant patients, 36 (38.29%) had acquired TKD mutations. Among 36 patients, mean BCR-ABL1 levels are significantly higher in b2a2 and b2a2 + b3a2 group (P = 0.0002; P ≤ 0.0001). TKD mutation frequency was more in b3a2 (61.11%) compared to other types. With respect to follow-up status in 36 patients, 17 patients died while 19 were on imatinib higher doses or 2nd-generation tyrosine kinase inhibitors. Of 17 patients, 41.66% had b2a2 transcript and 54.54% had b3a2 transcript. Conclusion: Patients with b3a2 transcripts might be associated with poor response and worse prognosis in CML with imatinib treatment.

Keywords

BCR-ABL1 - chronic myeloid leukemia - fusion transcripts - imatinib - response - tyrosine kinase domain mutations - polymerase chain reaction (P CR)

Publication History

Article published online:
23 June 2021

• References

• 1 Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-84
• 2 Prejzner W. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia. Med Sci Monit 2002; 8: BR193-7
• 3 Sharma P, Kumar L, Mohanty S, Kochupillai V. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts. Ann Hematol 2010; 89: 241-7
• 4 Adler R, Viehmann S, Kuhlisch E, Martiniak Y, Röttgers S, Harbott J. et al Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia. Eur J Haematol 2009; 82: 112-8
• 5 Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (P CR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186-9
• 6 Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA. et al. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia. Arch Iran Med 2008; 11: 247-51
• 7 Kagita S, Jiwtani S, Uppalapati S, Linga VG, Digumarti R. Early molecular response in chronic myeloid leukemia patients predicts future response status. Tumour Biol 2014; 35: 4443-6
• 8 Kagita S, Jiwtani S, Uppalapati S, Linga VG, Digumarti R. et al. Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India. Tumour Biol 2014; 35: 7187-93
• 9 Lichtman MA, Lieveld JL. Chronic myelogenous leukemia and related disorders. In: Beutler F, Lichtman MA, Coller BS, Kipps TJ. editors Williams Hematology. New York: New York: McGraw-Hill; 2001. 6. 1125-36
• 10 Rabinowitz I, Larson RS. Chronic myeloid leukemia. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Glader B. editors Wintrobe's Clinical Hematology. Philadelphia: Philadelphia: Lippincott Williams & Wilkins; 2004. 11. 2235-58
• 11 Deininger MW. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program 2008; 419: 26
• 12 Vardiman JW, Melo JV, Baccarani M, Thiele J. Myeloproliferative neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. et al.editors WHO Classification of Tumours Of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press: Lyon: IARC Press; 2008. p. 32-7
• 13 Ou J, Vergilio JA, Bagg A. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Am J Hematol 2008; 83: 296-302
• 14 Udomsakdi-Auewarakul C, U-Pratya Y, Boonmoh S, Vatanavicharn S. Detection of molecular variants of BCR-ABL gene in bone marrow and blood of patients with chronic myeloid leukemia by reverse-transcriptase polymerase chain reaction (RT-PCR). J Med Assoc Thai 2000; 83: 928-35
• 15 Rosas-Cabral A, Martínez-Mancilla M, Ayala-Sánchez M, Vela-Ojeda S, Bahena-Reséndiz P, Vadillo-Buenfil M. et al. Analysis of Bcr-abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia. Gac Med Mex 2003; 139: 553-9
• 16 de Lemos JA, de Oliveira CM, Scerni AC, Bentes AQ, Beltrão AC, Bentes IR. et al. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia. Genet Mol Res 2005; 4: 803-11
• 17 Al-Achkar W, Moassass F, Youssef N, Wafa A. et al. Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients. J BUON 2016; 21: 444-9
• 18 Anand MS, Varma N, Varma S, Rana KS, Malhotra P. Cytogenetic & molecular analyses in adult chronic myelogenous leukaemia patients in north India. Indian J Med Res 2012; 135: 42-8
• 19 Polampalli S, Choughule A, Negi N, Shinde S, Baisane C, Amre P. et al. Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts. Genet Mol Res 2008; 7: 1138-49
• 20 Deb P, Chakrabarti P, Chakrabarty S, Aich R, Nath U, Ray SS. et al. Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate. Indian J Med Paediatr Oncol 2014; 35: 26-30
• 21 Osman EA, Hamad K, Elmula IM, Ibrahim ME. Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients. Genet Mol Biol 2010; 33: 229-31
• 22 Martínez-Mancilla M, Gutiérrez M, de la Rosa GZ, García-Carrancá A, Miranda E. Younger age and shorter chronic phase in b2a2-positive chronic myeloid leukemia adults with high white blood cell count at diagnosis. Haematologica 2002; 87: 666-8
• 23 Perego RA, Costantini M, Cornacchini G, Gargantini L, Bianchi C, Pungolino E. et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer 2000; 36: 1395-401
• 24 Balatzenko G, Vundinti BR, Margarita G. Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia - A possible influence of mdr1 gene expression. Hematol Rep 2011; 3: e3
• 25 Farhat-Maghribi S, Habbal W, Monem F. Frequency of BCR-ABL transcript types in Syrian CML patients. J Oncol 2016; 2016: 8420853
• 26 Jain P, Kantarjian H, Patel KP, Kanagal ShamannaR. et al Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 2016; 127: 1269-75
• 27 Mir R, Ahmad I, Javid J, Zuberi M, Yadav P, Shazia R. et al. Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients. Indian J Cancer 2015; 52: 314-8